SparingVision Presents New Data on SPVN20 Program at ASGCT 2023
SparingVision Presents New Data on SPVN20 Program at ASGCT 2023 First oral presentation on SPVN20…
We are a clinical-stage genomic medicines company leading a step shift in how ocular diseases are treated. We are going beyond single gene correction therapies to deliver new treatments to patients affected by Inherited Retinal Diseases (IRDs), regardless of genetic cause.